Keynote 146 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Final outcomes from the phase 1b/2 Study 111/KEYNOTE-146 trial, evaluating treatment with lenvatinib and pembrolizumab in patients with advanced renal cell carcinoma, has sparked interest in the use of this combination.

Memorial sloan kettering cancer centerNew yorkUnited statesChan leeKidney cancer research summitChung han leeCancer research summitKeynote 146Advanced rcc